Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript
Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Good morning, everyone. Thank you so much for joining.
Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
